Appendix Cancer
21
7
12
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
4.8%
1 terminated out of 21 trials
83.3%
-3.3% vs benchmark
0%
0 trials in Phase 3/4
60%
3 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 5 completed trials
Clinical Trials (21)
ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
The Appendix Cancer PMP Research Foundation Natural History Study/Patient Registry
Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer
Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Target-specific immunoPET Imaging of Digestive System Carcinoma
Plasma 5hmC Signatures as a Marker of Colorectal / Appendiceal Peritoneal Metastasis
Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy
Genetics of Appendix Cancer Study
Diagnostic Value of Diffusion-weighted Magnetic Resonance in High-risk Colorectal and Appendiceal Neoplasms
The Registry of Oncology Outcomes Associated with Testing and Treatment
Intraperitoneal LSTA1 in CRS-HIPEC
Value of Right-sided Hemicolectomy for Chldren With High-risk Neuroendocrine Tumors of the Appendix
Perioperative Exercise and Nutritional Optimisation Prehabilitation Before Surgery for Patients With Peritoneal Malignancy
Programs To Support You During Chemotherapy
LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma
Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI
The Prevalence of Appendiceal Tumours in Periappendicular Abscess